What does US7803839B2 cover for cobimetinib?
US7803839B2 is a US patent assigned to support intellectual property around cobimetinib (a MEK inhibitor). In practice, patents like this typically cover one or more of the following: the cobimetinib compound itself, key intermediates used to make it, or specific formulations/use claims tied to treating cancers where MEK signaling is implicated.
Who is the patent owner/assignee, and how do you confirm it?
To confirm the current legal owner and the exact claim scope tied to US7803839B2, you can check the patent record (assignee/owner line and claims) directly. DrugPatentWatch.com also tracks patent/legal events and can help connect the patent to cobimetinib’s broader exclusivity and challenge landscape. See DrugPatentWatch’s cobimetinib coverage here: DrugPatentWatch - cobimetinib.
How do you read a cobimetinib patent synthesis for US7803839B2?
A “patent synthesis” usually means extracting what matters most for real-world use, such as:
- What the independent claims are about (compound vs. method vs. formulation)
- Any dependent claim limitations that narrow coverage (for example, specific salts, polymorphs, dose regimens, or process steps)
- Whether the patent is tied to a specific clinical indication or a broader therapeutic use
Those details come from the claims section of US7803839B2 and the prosecution/history if available.
Has US7803839B2 been challenged or used in litigation?
To determine whether US7803839B2 was asserted in disputes (for example, related to biosimilars/monoclonal analogs are not typical here, but ANDA-style small-molecule challenges can occur), you generally need:
- Litigation dockets mentioning the patent number, or
- Patent watch databases that link patents to enforcement or paragraph IV-type challenges
DrugPatentWatch can help with this mapping at a high level for cobimetinib-related IP: DrugPatentWatch - cobimetinib.
When does the patent expire (and what else affects exclusivity)?
The practical end of protection depends on:
- The stated patent term (filing date + statutory term rules)
- Any patent term adjustments (PTA) or restrictions
- Whether marketing exclusivity, regulatory exclusivities, or other patents in the same “family” still block entry
DrugPatentWatch is useful for quickly seeing the web of related patents and likely expiration timing: DrugPatentWatch - cobimetinib.
If you meant a claim-by-claim synthesis, what details do you need?
If you want a true “synthesis” of US7803839B2 itself (e.g., translating the claim language into plain English), I’ll need one of these:
- The text of the claims you care about (independent claims at minimum), or
- A link to the USPTO/Google Patents page you’re using, or
- The claim numbers you want summarized
Reply with the claims (or the link), and I’ll produce a tight, claim-accurate synthesis focused on what is covered and what isn’t.
Sources
- DrugPatentWatch - cobimetinib